Evidence map›Paper›PMID 36140513›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Prognostic Significance of the N-Terminal Pro-B-Type Natriuretic Peptide in Lung Transplant Candidates on the Waiting List.

Shimon Izhakian, Assaf Frajman, Lev Freidkin, Osnat Shtraichman, Dror Rosengarten, Barak Pertzov, Yaron D Barac, Mordechai Reuven Kramer

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shimon IzhakianPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.ORCID 0000-0003-1150-1057
Assaf FrajmanPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.ORCID 0000-0002-2256-4232
Lev FreidkinPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.
Osnat ShtraichmanPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.
Dror RosengartenPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.
Barak PertzovPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.
Yaron D BaracSackler Faculty of Medicine, Tel Aviv University, Ramat Aviv 6997801, Israel.
Mordechai Reuven KramerPulmonary Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva 4941492, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the prognostic significance of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in lung transplant candidates, in a retrospective single-center study. Data regarding various baseline characteristics and all-cause mortality were collected for 205 lung transplant candidates placed on waitlist for transplantation from November 2017 to December 2019. Associations of NT-proBNP levels with baseline characteristics and mortality were analyzed. Results showed NT-proBNP values correlated positively with age, forced vital capacity, mean pulmonary artery pressure (MPAP), and pulmonary capillary wedge pressure; and negatively with diffusing lung capacity for carbon monoxide and cardiac index. The optimal cut-off of NT-proBNP for predicting MPAP levels > 35 mmHg was 251 pg/mL; with 58.1% sensitivity, 85.7% specificity, 45.0% positive predictive value, and 91.0% negative predictive value. During a median follow-up period of 2.2 years, 97 patients underwent lung transplantation, 42 died waiting for donation, and 66 were alive and still waiting for transplantations. On multivariate analysis, higher NT-proBNP levels were strongly associated with increased mortality among waitlisted lung transplant candidates (HR 1.49, 95% CI 1.10−2.03, p = 0.01). In conclusion NT-proBNP can predict mortality among waitlisted lung transplant candidates. Lower levels of NT-proBNP can preclude severe pulmonary artery hypertension. Assessment of NT-proBNP may improve risk stratification among lung transplant candidates.

Indexed as

lung transplantationmortalityNT-proBNPprognosispulmonary hypertension

Identifiers

PMID36140513
PMCPMC9497763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.